| Recruiting | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignan NCT05800210 | University of Florida | Phase 2 |
| Recruiting | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Active Not Recruiting | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibito NCT05515029 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 |
| Recruiting | The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With NCT04726241 | PedAL BCU, LLC | Phase 1 / Phase 2 |
| Recruiting | A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation NCT04024761 | Dana-Farber Cancer Institute | Phase 1 |
| Active Not Recruiting | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation NCT03843528 | Johns Hopkins All Children's Hospital | Phase 1 |
| Recruiting | CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT NCT03810196 | Children's Hospital of Philadelphia | N/A |
| Active Not Recruiting | Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia NCT03190915 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Withdrawn | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferati NCT02564536 | Washington University School of Medicine | Phase 1 |
| Completed | Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia NCT04082286 | Great Ormond Street Hospital for Children NHS Foundation Trust | Phase 1 |
| Completed | Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplan NCT02458235 | University of California, San Francisco | Phase 2 |
| Unknown | Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood He NCT02338479 | Center for International Blood and Marrow Transplant Research | — |
| Completed | Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cel NCT01824693 | Children's Oncology Group | Phase 2 |
| Terminated | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in P NCT01621477 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Unknown | Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological M NCT01339988 | Tel-Aviv Sourasky Medical Center | Phase 4 |
| Completed | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or NCT01305200 | Children's Oncology Group | Phase 3 |
| Completed | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Completed | A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for NCT01036009 | University of California, San Francisco | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Completed | Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other NCT00450450 | Children's Oncology Group | Phase 3 |
| Terminated | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in NCT00852709 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancie NCT00697671 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia NCT01445080 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Tr NCT00309907 | Children's Oncology Group | Phase 2 |
| Unknown | Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leu NCT00662090 | University Hospital Freiburg | — |
| Completed | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, NCT00217412 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies NCT00143559 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML NCT00669890 | New York Medical College | Phase 1 |
| Completed | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With NCT00898079 | Children's Oncology Group | — |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia NCT01020539 | Columbia University | Phase 1 |
| Completed | Stem Cell Transplantation for Patients With Hematologic Malignancies NCT00152139 | St. Jude Children's Research Hospital | Phase 3 |
| Completed | Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children NCT00025038 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) NCT00167219 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |